DSIP 5mg
Endogenous nonapeptide examined in experimental protocols for slow-wave sleep architecture, circadian rhythm modulation, and stress response.
Mechanism
DSIP acts as an endogenous neuromodulator that promotes delta-wave slow-wave sleep rhythms and tempers HPA axis activity via putative interactions with central GABAergic and opioid transmission networks.
Dosing
Published research protocols document a daily starting level of 100 mcg administered subcutaneously, titrated upward gradually based on study design.
Reconstitution
Reconstituting a 5 mg vial with 3.0 mL of bacteriostatic water produces an approximate concentration of 1.67 mg/mL (16.7 mcg per U-100 unit).
Storage
Store the dry lyophilized compound at -20 °C, and preserve the reconstituted solution between 2 °C and 8 °C protected from light, avoiding repeated freeze-thaw cycles.
Mix & measure DSIP 5mg
Pre-filled with this protocol's recommended BAC water and documented starting dose — edit any field to run your own numbers.
Mix & measure DSIP 5mg
Vial strength → BAC water → target dose
Common vial sizes
Label claim
Total doses in vial: 50.0
U-100 syringe: 100 units = 1 mL
Need supplies for this protocol?
Research-grade peptides, fast shipping, competitive pricing
Reconstitution math only — not dosing advice. U-100 syringe: 100 units = 1 mL. Advanced calculator →
Track my protocol
Log each dose, build a streak, and watch your progress through this protocol's schedule.
Dosing Chart
| Phase / Day(s) | Dose & Frequency | Volume (U-100 units / mL) |
|---|---|---|
| Week 1 | 100 mcg (1× daily) | 6 units (0.06 mL) |
| Week 2 | 150 mcg (1× daily) | 9 units (0.09 mL) |
| Week 3 | 200 mcg (1× daily) | 12 units (0.12 mL) |
| Weeks 4–8 | 250–300 mcg (1× daily) | 15–18 units (0.15–0.18 mL) |
Reconstitution Steps
- 1
Aseptically clean the rubber septums of both the DSIP and bacteriostatic water vials using fresh sterile alcohol pads.
- 2
Draw exactly 3.0 mL of bacteriostatic water into a sterile syringe.
- 3
Introduce the needle into the DSIP vial and discharge the diluent gently along the interior glass wall to minimize turbulent agitation and foaming.
- 4
Gently swirl and invert the vial until the lyophilized cake is fully dissolved without vigorous shaking.
- 5
Affix a label noting reconstitution date and working concentration, then store immediately at 2–8 °C.
Supplies Needed
Peptide Vial
Contains 5 mg of lyophilized DSIP research material
Insulin Syringes (U-100)
Used for precise measurement and subcutaneous delivery of micro-volume allocations
Bacteriostatic Water
Provides 3.0 mL of preserved sterile diluent required for reconstitution
Alcohol Swabs
Used to maintain sterile technique on vial stoppers and injection sites
Why researchers study it
Slow-wave (delta) sleep induction and architecture preservation
Hypothalamic-pituitary-adrenal (HPA) axis stress modulation
Central analgesic mechanisms and pain perception pathways
Preclinical neuroprotection and mitigation of oxidative strain
These describe what is being studied, not proven benefits, approved uses, or promised results.
Overview
Delta Sleep-Inducing Peptide (DSIP) is an endogenous nonapeptide consisting of nine amino acids (Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu) that was originally isolated from the cerebral venous blood of rabbits undergoing low-frequency electrical stimulation. Historically investigated for its regulatory influence on sleep macro-architecture, experimental interest centers on its capacity to selectively facilitate delta EEG rhythms without suppressing REM phases. Unlike standard sedative-hypnotics, it does not induce immediate narcosis but rather appears to modulate physiologic restorative patterns. Beyond basic sleep physiology, laboratory literature describes broader adaptogenic and neuromodulatory properties. DSIP has been evaluated for its potential interactions with the central neuroendocrine axes, specifically attenuating stress responses driven by the hypothalamic-pituitary-adrenal (HPA) cascade. Researchers have highlighted its ability to preserve cellular integrity during biochemical or oxidative strain in preclinical neural models. DSIP remains an unregulated, investigational chemical strictly restricted to preclinical research settings. Because human trials remain dated and limited, standardized clinical parameters do not exist. Experimental laboratory inquiries are aimed at dissecting its elusive secondary signaling pathways, receptor affinity, and neurochemical effects across animal models.
References
- 1.Schoenenberger GA, Monnier M, Proc Natl Acad Sci USA, 1977 — Characterization of a delta-electroencephalogram (-sleep)-inducing peptide isolated from rabbit brain
- 2.Editorial Review, European Journal of Anaesthesiology, 2001 — Delta sleep-inducing peptide: editorial review of proposed mechanisms and clinical context
- 3.Schneider-Helmert D, Schoenenberger GA, Neuropsychobiology, 1983 — Effects of DSIP in man: multifunctional psychophysiological properties
- 4.Sudakov KV et al., Ann N Y Acad Sci, 2004 — Delta-sleep-inducing peptide sequelae: stress-protective effect
- 5.Schneider-Helmert D, Int J Clin Pharmacol Ther Toxicol, 1981 — Acute and delayed effects of DSIP on human sleep behavior
- 6.Graf MV, Kastin AJ, Neurosci Biobehav Rev, 1984 — Delta-sleep-inducing peptide (DSIP): a review
- 7.Wang W, Int J Pharm, 2000 — Lyophilization and development of solid protein pharmaceuticals (stability and storage)
- 8.Manning MC et al., Pharm Res, 2010 — Stability of protein pharmaceuticals: an update
- 9.Yehuda S, Carasso RL, Int J Neurosci, 1988 — DSIP: proposed brain mechanisms and function
- 10.Khvatova EM et al., Biull Eksp Biol Med, 2003 — Delta sleep-inducing peptide: effect on oxidative stress in brain
Supplies Needed
Suggested supplier
Research use only. Listing a supplier is not an endorsement of any protocol on this site, and nothing sold there is approved for human use.
Related protocols
View allSemax 10mg
A synthetic heptapeptide ACTH(4-10) derivative investigated in preclinical models for neurotrophic signaling, focus, and neuroprotection.
View ProtocolMGF 5mg
Mechano Growth Factor (IGF-1Ec) splice variant investigated in preclinical literature for myogenic satellite cell activation and localized repair.
View ProtocolDermorphin 5mg
Natural amphibian heptapeptide exhibiting exceptional mu-opioid receptor affinity and metabolic stability via an unusual D-amino acid.
View Protocol